Compounded GLP-1 Laws by State: 2026 Regulatory Guide

Whether you can access compounded GLP-1 medications doesn't just depend on federal law — it depends on where you live. While the FDA sets the federal framework through Sections 503A and 503B of the FD&C Act, individual state pharmacy boards add their own restrictions, enforcement patterns, and compliance requirements that create a patchwork of access across the country.

Here's the current landscape as of May 2026, organized by how states are approaching compounded GLP-1 regulation.

The Federal Baseline (Applies Everywhere)

Before diving into state variations, here's what applies nationally:

503A pharmacies (state-licensed) can compound patient-specific prescriptions under state pharmacy board oversight. They cannot make "essentially a copy" of a commercially available drug unless it's on the FDA shortage list (which semaglutide and tirzepatide are no longer on) or the patient has documented clinical justification for a personalized formulation.

503B outsourcing facilities (FDA-registered) operate under federal cGMP standards, submit to biannual FDA inspections, and can compound larger batches for healthcare entities. They rely on the 503B Bulks List — and the FDA has proposed excluding semaglutide, tirzepatide, and liraglutide from that list (comment period open through June 29, 2026).

States Tightening Restrictions

California — Most Aggressive Enforcement

California's Board of Pharmacy has issued more than 30 enforcement actions against peptide-compounding pharmacies since 2023. Empower Pharmacy's nonresident sterile compounding permit has been on probation in California since 2022. The state applies the strictest interpretation of the "essentially a copy" standard and actively investigates telehealth platforms selling compounded GLP-1s to California residents.

Indiana — New Legislative Framework

Indiana SB 282, which passed the Senate in January 2026, requires 503A and 503B compounding pharmacies to comply with federal law and authorizes enforcement by the Indiana Board of Pharmacy. The bill also creates a medical spa registration framework effective January 1, 2027. This is the first state bill to explicitly create a state-level enforcement mechanism for federal compounding standards around GLP-1s.

New Jersey — Enhanced Quality Controls

New Jersey introduced legislation requiring bulk drug substance quality controls, certificates of analysis documentation, and additional testing requirements — creating a "state-level extra layer" beyond the federal baseline. This template could be copied by other states.

Ohio — Published Specific Guidance

Ohio published specific peptide compounding guidance in February 2026, adding state documentation requirements beyond federal minimums. This includes additional record-keeping obligations that go beyond what the FDA requires for 503A pharmacies.

States With Less Aggressive Enforcement

Texas — Significant Compounding Activity

Texas hosts some of the largest compounding operations in the country (including Empower Pharmacy in Houston). While the Texas State Board of Pharmacy maintains oversight, enforcement has been less aggressive than California's. Many major GLP-1 compounding lawsuits are litigated in Texas federal courts, including both the Eli Lilly and OFA v. FDA cases.

Florida — Mixed Signals

Florida saw a compounder victory in May 2025 when a federal court dismissed Novo Nordisk's suit against Brooksville Pharmaceuticals. However, the state board maintains active oversight and has not relaxed compounding standards.

What Your State Means for You

Does Your State Matter if You Use Telehealth?

Yes — but less than you might think. Telehealth-based compounding providers typically ship from a pharmacy in one state to a patient in another. What matters is the pharmacy's home state license (where they compound), the receiving state's regulations on nonresident pharmacy permits, and whether the pharmacy holds a valid nonresident compounding license in your state.

Reputable providers handle this licensing automatically. If a provider tells you they "can't ship to your state," they may lack the proper nonresident permits — which is actually a useful red flag for due diligence.

The Trend: More Regulation, Not Less

The direction is clear. At both federal and state levels, the regulatory environment for compounded GLP-1s is tightening. The FDA's April 1, 2026 guidance clarifying the "essentially a copy" standard, the proposed 503B Bulks List exclusion, and state-level bills like Indiana's SB 282 all point toward a future with more oversight, not less.

This isn't necessarily bad for patients. Better-regulated compounding means higher-quality products from the pharmacies that survive the regulatory shake-out. But it does mean that the era of loosely regulated, cheaply produced compounded GLP-1s is ending.